Current Clinical Trials

You may be eligible to take part in one of the many clinical trials underway at the UCI Alpha Stem Cell Clinic. By participating in a clinical trial, patients have access to leading-edge treatments and therapies long before they are available to the general public.

The more you know about clinical trials, the better informed you will be when deciding whether to participate in a specific trial. Click on the get more information buttons to see trial specifics on the Center for Clinical Trials website.

The UCI Center for Clinical Research oversees clinical trials for UCI Health and the UCI School of Medicine. Trials cover the full spectrum of conditions, from heart disease, neurological disorders, visual impairment, and more. Please visit the center's website to search for open clinical trials

Questions or comments? Email us at 

Aspen Neurosciences Developing a Trial Ready Cohort of Parkinson Disease Patients – PI: Nicolas Phielippp

Nicolas Phielipp, M.D.

Cabaletta Bio, Inc. Phase 1 MuSK-CAART for Subjects with Anti-MuSK Antibody Positive MG

Ali Habib, M.D.

AskBio Glial Cell Line-Derived Neurotrophic Factor Gene Transfer in Multiple System Atrophy

Nicolas Phielipp, M.D.

Audentes FORTIS Gene Transfer Study in Patients with Late Onset Pompe Disease

Tahseen Mozaffar, M.D.

Cartesian Descartes-08 Generalized Myasthenia Gravis Clinical Trial

Tahseen Mozaffar, M.D.

Immunis, Inc. Open Label Use of IMM01-STEM in Patients with Muscle Atrophy Related to Knee Osteoarthritis

Dean Wang, M.D. 

Regeneron Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in patients with symptomatic generalized Myasthenia Gravis

Ali Habib, M.D.

Sangamo ST-920 A Gene Therapy in Subjects with Fabry Disease

Madeleine Pahl, M.D.

Direct Biologics, Evaluating the Efficacy of EXOFLO in Treating Moderate to Severe ARDS Caused by COVID-19

Alpesh Amin, M.D.

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Dr. Nicolas Phielipp, M.D.

Safety and efficacy of LION-101 in subjects (ages 5-65) with LGMD2I/R9 impacting FKRP

Dr. Tahseen Mozaffar, M.D.

Study Evaluating Variability, Reliability, and Compliance for the Parkinson's Disease Diary

Dr. Claire Henchcliffe, M.D.

Evaluate the Safety & Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy

Tahseen Mozaffar, M.D.